Cargando…

Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination

The kinetics of Fc-mediated functions following SARS-CoV-2 infection or vaccination in people living with HIV (PLWH) are not known. We compared SARS-CoV-2 spike-specific Fc functions, binding, and neutralization in PLWH and people without HIV (PWOH) during acute infection (without prior vaccination)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Motsoeneng, Boitumelo M., Manamela, Nelia P., Kaldine, Haajira, Kgagudi, Prudence, Hermanus, Tandile, Ayres, Frances, Makhado, Zanele, Moyo-Gwete, Thandeka, van der Mescht, Mieke A., Abdullah, Fareed, Boswell, Michael T., Ueckermann, Veronica, Rossouw, Theresa M., Madhi, Shabir A., Moore, Penny L., Richardson, Simone I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435738/ https://www.ncbi.nlm.nih.gov/pubmed/37600825 http://dx.doi.org/10.3389/fimmu.2023.1231276

Ejemplares similares

Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2022)

SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity
por: Richardson, Simone I., et al.
Publicado: (2022)

Enhanced neutralization potency of an identical HIV neutralizing antibody expressed as different isotypes is achieved through genetically distinct mechanisms
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2022)

Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern
por: Kitchin, Dale, et al.
Publicado: (2022)

Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variant
por: Richardson, Simone I., et al.
Publicado: (2022)

SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals
por: Richardson, Simone I., et al.
Publicado: (2022)

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2021)

SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2021)

Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2023)

Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2023)

Infection pre-Ad26.COV2.S-vaccination primes greater class switching and reduced CXCR5 expression by SARS-CoV-2-specific memory B cells
por: Krause, Robert G. E., et al.
Publicado: (2023)

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
por: Wibmer, Constantinos Kurt, et al.
Publicado: (2021)

HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function
por: Richardson, Simone I., et al.
Publicado: (2021)

Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant
por: Ryu, Dong-Kyun, et al.
Publicado: (2021)

Comparison of platelet-and endothelial-associated biomarkers of disease activity in people hospitalized with Covid-19 with and without HIV co-infection
por: van der Mescht, Mieke A., et al.
Publicado: (2023)

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages
por: Bhiman, Jinal N., et al.
Publicado: (2023)

Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies
por: Scheepers, Cathrine, et al.
Publicado: (2022)

Decline in antibody responses to SARS-CoV-2 post-vaccination poses a risk to health care workers
por: Worsley, Catherine M., et al.
Publicado: (2022)

Influenza Vaccination Results in Differential Hemagglutinin Stalk-Specific Fc-Mediated Functions in Individuals Living With or Without HIV
por: Motsoeneng, Boitumelo M., et al.
Publicado: (2022)

Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner
por: Keeton, Roanne, et al.
Publicado: (2021)

SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021
por: Mandolo, Jonathan, et al.
Publicado: (2021)

Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial
por: Madhi, Shabir A, et al.
Publicado: (2023)

AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2
por: Chibwana, Marah G., et al.
Publicado: (2022)

Escape from recognition of SARS-CoV-2 Beta variant spike epitopes but overall preservation of T cell immunity
por: Riou, Catherine, et al.
Publicado: (2022)

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial
por: Madhi, Shabir A, et al.
Publicado: (2021)

The Burden of Pertussis Hospitalization in HIV-Exposed and HIV-Unexposed South African Infants
por: Soofie, Nasiha, et al.
Publicado: (2016)

Inhibition of replication of hepatitis B virus using transcriptional repressors that target the viral DNA
por: Bloom, Kristie, et al.
Publicado: (2019)

Genome Analysis of A Novel South African Cydia pomonella granulovirus (CpGV-SA) with Resistance-Breaking Potential
por: Motsoeneng, Boitumelo, et al.
Publicado: (2019)

Elicitation of Neutralizing Antibody Responses to HIV-1 Immunization with Nanoparticle Vaccine Platforms
por: Murji, Amyn A., et al.
Publicado: (2021)

Author Correction: T cell responses to SARS-CoV-2 spike cross-recognize Omicron
por: Keeton, Roanne, et al.
Publicado: (2022)

T cell responses to SARS-CoV-2 spike cross-recognize Omicron
por: Keeton, Roanne, et al.
Publicado: (2022)

Approach to acute kidney injury in HIV-infected patients in South Africa
por: Boswell, Michael T., et al.
Publicado: (2017)

SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape
por: Cele, Sandile, et al.
Publicado: (2022)

SARS-CoV-2 evolved during advanced HIV disease immunosuppression has Beta-like escape of vaccine and Delta infection elicited immunity
por: Cele, Sandile, et al.
Publicado: (2021)

Needle-Free Devices and CpG-Adjuvanted DNA Improve Anti-HIV Antibody Responses of Both DNA and Modified Vaccinia Ankara-Vectored Candidate Vaccines
por: Chapman, Rosamund, et al.
Publicado: (2023)

Development of a growth monitoring and promotion index to improve child health in Zimbabwe
por: Moyo, Shamiso Alice, et al.
Publicado: (2022)

Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition
por: Gilbert, Peter B., et al.
Publicado: (2022)

Sequence and functional characterization of a public HIV-specific antibody clonotype
por: Murji, Amyn A., et al.
Publicado: (2021)

Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials
por: Mkhize, Nonhlanhla N., et al.
Publicado: (2023)

Growth Monitoring and Promotion Index Development: A Novel Approach
por: Moyo, Shamiso Alice, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nc3hv7980gjdf74b79u1udku0p